# US 12,005,066 B2 · Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,066 B2
- Document ID: US12005066B2
- Status: Granted
- Kind: B2
- Application number: 15/734,254
- Filed: 2019-06-04
- Published: 2021-07-15
- Granted: 2024-06-11
- Earliest claimed: 2018-06-04
- Assignees: The Regents of the University of California; The Regents of the University of Colorado
- Applicants: The Regents of the University of California; The Regents of the University of Colorado
- Inventors: Gerard Boss; Adriano Chan; Matthew Brenner; Sari Brenner Mahon; Vikhyat Bebarta
- Web page: https://patentgrep.com/patent/US12005066B2

## CPC

- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 39/02: Antidotes
- C07F 15/065: {without a metal-carbon linkage}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Methods and compositions for treating cyanide, sulfide, or methane-thiol exposure in a subject. The compositions may include one or more cobinamide compounds, such as an amino-tetrazole-cobinamide and/or a di-(amino-tetrazole)-cobinamide.

## Claims

### Claim 1

A method for ameliorating one or more symptoms associated with cyanide exposure, sulfide exposure, or methane thiol exposure in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of one or more cobinamide compounds; wherein the one or more cobinamide compounds is selected from the group consisting of an amino-tetrazole-cobinamide, a di-(amino-tetrazole)-cobinamide, an acetyl-tetrazole-cobinamide, and a di-(acetyl-tetrazole)-cobinamide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amino-tetrazole-cobinamide comprises 5-amino-tetrazole-cobinamide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the di-(amino-tetrazole)-cobinamide comprises di-(5-amino-tetrazole)-cobinamide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the acetyl-tetrazole-cobinamide comprises 5-acetyl-tetrazole-cobinamide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the di-(acetyl-tetrazole)-cobinamide comprises di-(5-acetyl-tetrazole)-cobinamide.

### Claim 6 (depends on 1)

The method of claim 1, wherein the effective amount of the one or more cobinamide compounds is about 8 mg/kg to about 24 mg/kg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier to facilitate the amelioration of one or more symptoms.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a sterile solution or a sterile suspension.

### Claim 9

A pharmaceutical composition comprising one or more cobinamide compounds, wherein the one or more cobinamide compounds is selected from the group consisting of an amino-tetrazole-cobinamide, a di-(amino-tetrazole)-cobinamide, an acetyl-tetrazole-cobinamide, and a di-(acetyl-tetrazole)-cobinamide.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the amino-tetrazole-cobinamide comprises 5-amino-tetrazole-cobinamide.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the di-(amino-tetrazole)-cobinamide comprises di-(5-amino-tetrazole)-cobinamide.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9, wherein the acetyl-tetrazole-cobinamide comprises 5-acetyl-tetrazole-cobinamide.

### Claim 13 (depends on 9)

The pharmaceutical composition of claim 9, wherein the di-(acetyl-tetrazole)-cobinamide comprises di-(5-acetyl-tetrazole)-cobinamide.

### Claim 14 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 15 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is a sterile solution or a sterile suspension.

### Claim 16 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is formulated for intramuscular delivery.